drugset / Trial / NCT00555087

Treatment of Erectile Dysfunction in Hypogonadal Men With Testosterone Undecanoate

NCT00555087

Phase 4 Unknown 50 enrolled Hospital Santa Fe Bayer · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The main objective of this study is to evaluate the response of erectile dysfunction in hypogonadotrophic males with Testosterone undecanoate i.m. as per IIEF and the question of the GAQ (Global Evaluation Questionnaire) after 42 weeks of treatment. Secondary Study Objectives * To monitor adverse events and changes in hemoglobin and serum chemistry with: PSA, lipid profile, renal-hepatic profile and glycemia, and control by means of a rectal digital examination. * To Determinate physiologic reconstitution in patients under treatment by means of total and free testosterone dosage.

Timeline

Start
2007-05
Primary completion
Completion
2008-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Testosterone Undecanoate Small molecule 1000 mg Intramuscular
Background Vardenafil Small molecule 20 mg